Novel delivery technologies: Triggering the Biopharmaceutical potential of Boswellic acids

Abstract

Boswellic acids are series of pentacyclic triterpenes, derived from the gum resin of Boswellia Genus, mostly from Boswellia serrata Roxb. (Burseraceae) tree commonly known as Indian Frankincense or salai guggul and traditionally used as an anti-inflammatory agent. It acts by inhibiting 5-Lipoxygenase, C3-convertase, cyclooxygenase preferably COX-1, Human Leukocyte Elastase, NF-κB expression, Topoisomerase I and II and microsomal Prostaglandin E2 synthase-1. Boswellia species are reported to have various pharmacological potentials like anti-inflammatory, anti-cancer, anti-microbial, anti-arthritic, immunomodulatory activity, neuroprotective activity, and are also proved to be effective against ileitis, ulcerative colitis, hypolipidemic, hypertension and hepatotoxicity. Regardless of their multiple uses, pharmacokinetic studies of Boswellic acids revealed their poor oral bioavailability, high lipophilicity, and their degradation by hepatic Phase I mechanism. With low solubility and poor bioavailability, different approaches have been applied to improve the poor pharmacokinetic profile of Boswellic acids. Designing and developing novel delivery systems for its enhanced permeability, improved bioavailability with better efficacy has been of great interest.